Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2018

View Archived Issues

Lack of LAC is depression target, biomarker

High-fat diet leads to hair loss?

Enzyme discovery may improve drug design

Medicenna's IL-2 superkine shows promising preclinical activity

Neurodegenerative differences found between the presubiculum and entorhinal cortex in AD

JCR Pharmaceuticals presents data for JR-141 in mucopolysaccharidosis type II

HitGen to identify potential new therapies for tuberculosis and malaria

Salix enters microbiome collaboration with Cedars-Sinai Medical Center

Immatics begins phase I study of IMA-202 in solid tumors

IL-23 underlies the development of castration-resistant prostate cancer

DrugCendR recruiting participants for phase I study of CEND-1 in metastatic pancreatic cancer

Potential mechanism of purinergic receptor-mediated remyelination discovered

Global collaboration to develop first-in-class gene therapy for cystic fibrosis

U.S. researchers patent Nampt activators

Rodin Therapeutics presents HDAC1 and HDAC2 inhibitors

XinXiang Medical University divulges ANO5-targeting siRNAs

Regeneron, bluebird bio to jointly discover immune cell therapies for cancer

First patient dosed in extension cohort of amcure's phase I/Ib study of AMC-303

Phase II study of telacebec in tuberculosis begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...